Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation

Anti-Cancer Agents in Medicinal Chemistry, 11(8): 729-738.

Author(s): Marianela Candolfi, Kurt M. Kroeger, Weidong Xiong, Chunyan Liu, Mariana Puntel, Kader Yagiz, AKM Ghulam Muhammad, Yohei Mineharu, David Foulad, Mia Wibowo, Hikmat Assi, Gregory J. Baker, Pedro R. Lowenstein and Maria G Castro.

Affiliation: Department of Neurosurgery, Department of Cell and Developmental Biology, University of Michigan School of Medicine, 4570 MSRB II, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0650.


Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. GBM is very aggressive due to its poor cellular differentiation and invasiveness, which makes complete surgical resection virtually impossible. Therefore, GBMs invasive nature as well as its intrinsic resistance to current treatment modalities makes it a unique therapeutic challenge. Extensive examination of human GBM specimens has uncovered that these tumors overexpress a variety of receptors that are virtually absent in the surrounding non-neoplastic brain. Human GBMs overexpress receptors for cytokines, growth factors, ephrins, urokinase-type plasminogen activator (uPA), and transferrin, which can be targeted with high specificity by linking their ligands with highly cytotoxic molecules, such as Diptheria toxin and Pseudomonas exotoxin A. We review the preclinical development and clinical translation of targeted toxins for GBM. In view of the clinical experience, we conclude that although these are very promising therapeutic modalities for GBM patients, efforts should be focused on improving the delivery systems utilized in order to achieve better distribution of the immuno-toxins in the tumor/resection cavity. Delivery of targeted toxins using viral vectors would also benefit enormously from improved strategies for local delivery.


IL-13, IL-13Rα2, TGF-α, EGFR, EGFRvIII, pseudomonas exotoxin, diphtheria toxin, gene therapy, targeted toxins.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 8
First Page: 729
Last Page: 738
Page Count: 10
DOI: 10.2174/187152011797378689
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science